PCAC Briefing · Thursday, July 23, 2026
BPC-157 before the compounding committee
FDA proposes not adding either BPC-157 substance to the 503A Bulks List. Its case rests on four points: the substances are not well characterised, there is a lack of information on safety and immunogenicity, the evidence is insufficient to conclude BPC-157 works for ulcerative colitis, and several approved drugs already treat ulcerative colitis — a serious chronic disease that can cause life-threatening complications.
Published July 16, 2026 · By the Grey Peptides Editorial Board · ✓ Sourced from FDA's briefing document
| Substances | BPC-157 (free base) and BPC-157 acetate |
| Also known as | Body Protection Compound 157, Bepecin, PL-14736 |
| Length | 15 amino acids (pentadecapeptide) |
| Use FDA reviewed | Ulcerative colitis |
| Forms proposed | Oral capsule (250 µg, 500 µg, 1 mg); subcutaneous injection (2,000 µg/mL); nasal spray (50 µg/spray); rectal suppository (1 mg); transdermal cream |
| Nomination | Wells Pharmacy Network and LDT Health Solutions (International Peptide Society) |
| FDA staff position | Proposes not adding either form to the 503A Bulks List |
What FDA reviewed it for
Nominated for ulcerative colitis, Crohn's disease, coeliac disease and tendonitis. FDA evaluated only ulcerative colitis — it said the nomination did not contain enough information to assess the other three, and it found no clinical studies of BPC-157 in those populations.
This is not a detail to skip past. FDA evaluates a bulk drug substance in the context of the use proposed for it — so the question in front of the committee is not "is BPC-157 useful?" but "does the evidence support compounding BPC-157 for ulcerative colitis?" A substance can have an interesting research literature in a completely different area and still fail this test, because that literature was never the thing under review.
FDA's specific objections
FDA weighs four criteria: whether the substance is well characterised physically and chemically, whether it has been used historically in compounding, what evidence exists on effectiveness, and what safety issues its use in compounding raises. Here is where BPC-157 landed on each.
FDA treats BPC-157 (free base) and BPC-157 acetate as two different active ingredients, and says both are inadequately characterised. Two reasons: naming that does not follow established chemical nomenclature standards (USAN, INN, IUPAC), and missing or inadequate data on quality attributes needed to establish identity, purity and quality for the proposed dosage forms.
A theme running through the whole document: FDA repeatedly notes it is often unclear whether the BPC-157 described in a given published paper is the free base or the acetate salt. That ambiguity limits what the literature can be used to prove about either substance specifically.
FDA concluded there is insufficient evidence to reach a conclusion on whether BPC-157 is effective for ulcerative colitis.
Nonclinical toxicology was limited in scope and duration for the proposed routes of administration. FDA notes the nomination did not include, and it is not aware of, information showing BPC-157 does not present immunogenicity risk — particularly by rectal or transdermal routes.
What is specific to BPC-157
Six of the seven objections above could be written about almost any of the compounds on the July agenda. These next points could not — they are what makes this file different from the other six.
FDA searched its Adverse Event Reporting System and describes case reports involving compounded BPC-157 — including a 15 mg-per-vial compounded acetate injection used for inflammation and injury, another compounded injection supplied by a compounding pharmacy, and a report involving a combined BPC-157 and TB-500 product labelled for research purposes only. This is the only one of the seven where FDA cites FAERS cases involving compounded product.
FDA notes BPC-157 is marketed in the US as an ingredient in dietary supplement capsules and tablets, and that there is no USP dietary supplement monograph for it.
The briefing document quotes clinic marketing calling BPC-157 the “wolverine compound.” FDA's inclusion of this is not incidental — the promotional framing around a substance forms part of the historical-use record it weighs.
The evidence picture
Grey Peptides grades BPC-157's evidence base as low. That grade predates this meeting and is unchanged by it. The overwhelming majority of BPC-157 research is animal work, much of it from a single research group. The human data FDA could find was not sufficient to support a conclusion either way on ulcerative colitis.
Two readings of the same file are worth separating. FDA's conclusion is about a regulatory question — whether the record supports letting pharmacists compound this substance for this use. That is a higher bar than "there is some interesting science here," and a lower bar than "this substance is harmful." Almost everything FDA said about BPC-157 is a statement about missing information, not a finding of harm. Reporting that as "FDA says BPC-157 is dangerous" is wrong. So is reporting it as "FDA found no safety problems."
Where this sits in our encyclopedia
Our entry on this compound covers the underlying pharmacology, the published literature, and the status picture independent of this meeting. The two are separate reads: the encyclopedia entry is about the compound, and this page is about the regulatory file.
Mechanism, evidence grade, half-life, approval status, and sources. PCAC July 2026 — the full picture
All seven compounds, what the vote does and doesn't change, and what to watch. Peptide Regulatory Status Tracker
Category 1/2/3, 503A vs 503B, and where every peptide sits.
The other six compounds
KPV · TB-500 · MOTS-c · Emideltide (DSIP) · Semax · Epitalon
FDA — July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee ↗
FDA briefing documents released June 29, 2026. Federal Register notice 91 FR 20465, published April 16, 2026 (FR Doc. 2026-07361), Docket No. FDA-2025-N-6895. FDA Briefing Document for BPC-157 (free base) and BPC-157 acetate, released June 29, 2026.